Cardiome Pharma Corp. today announced that its Chinese development and commercialization partner, Eddingpharm, plans to initiate a Phase 1 study for BRINAVESSTM to support regulatory approval in China. The study will be conducted in healthy volunteers.

Originally posted here:
Eddingpharm plans to begin Phase 1 study for BRINAVESS in China

Scroll to Top